heart iconheart icon
Skip to content

Press Releases

 
Press Releases
  Date Title and Summary View
Jun 20, 2017
NEW BRUNSWICK, N.J., June 20, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 18th, to review second-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer; Dominic Caruso, Executive Vice President, Chief Financial Officer and Joseph J. Wolk, Vice...
Jun 16, 2017
NEW BRUNSWICK, N.J., June 16, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash. The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, to ac...
Jun 14, 2017
Jun 14, 2017
Jun 12, 2017
Jun 9, 2017
NEW BRUNSWICK, N.J., June 9, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that, with today's receipt of approval of the proposed acquisition of Actelion Ltd (SIX: ATLN) from the European Commission (EC), all regulatory approvals required to complete the transaction have been received. Johnson & Johnson expects the settlement o...
Jun 1, 2017
May 25, 2017
NEW BRUNSWICK, N.J., May 25, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15, at the Terranea Resort in Rancho Palos Verdes, California.  Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Company in a session sc...
May 17, 2017
NEW BRUNSWICK, N.J., May 17, 2017 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders of Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies will announce plans to launch or file for regulatory approval more than 10 new products with blockbuster potential between 2017 and 2021, as well as 50-plus line extens...
May 15, 2017
IRVINE, Calif., May 15, 2017 /PRNewswire/ -- Biosense Webster, Inc., part of the Johnson & Johnson Medical Devices Companies*, recently announced clinical trial results from a first-in-human study evaluating the acute feasibility of an investigational radiofrequency (RF) balloon catheter in treating patients with atrial fibrillation, or Afib. The s...
Page:
1
... NextLast
= add release to Briefcase